Enanta Pharmaceuticals (ENTA) Net Equity Issued and Repurchased (2018 - 2019)
Enanta Pharmaceuticals' (ENTA) quarterly Net Equity Issued and Repurchased came in at $709000.0 in Q3 2019, down 32.6% YoY from $1.1 million in Q3 2018, and up 38.48% on a QoQ basis from $512000.0 in Q2 2019.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Net Equity Issued and Repurchased (2018 - 2019) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $709000.0 in Q3 2019.
- Quarterly Net Equity Issued and Repurchased fell 32.6% year-over-year to $709000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $5.3 million (changed N/A YoY) and the FY2021 annual result came in at $3.6 million, down 65.52% from the prior year.
- Net Equity Issued and Repurchased improved to $709000.0 in Q3 2019, from $512000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $3.0 million in Q2 2018 to a low of $512000.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Enanta Pharmaceuticals | 404.93 Mn | 215.43 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 709,000.00 |
| Jun 30, 2019 | 512,000.00 |
| Sep 30, 2018 | 1.05 Mn |
| Jun 30, 2018 | 2.99 Mn |